XML 42 R32.htm IDEA: XBRL DOCUMENT v3.25.2
Summary of Significant Accounting Policies (Details) - USD ($)
 3 Months Ended 6 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2025
Jun. 30, 2024
Dec. 31, 2024
Summary of Significant Accounting Policies [Line Items]          
Accounts receivable $ 117,651   $ 117,651   $ 121,582
Allowance for doubtful accounts 77,908   77,908   78,147
Investment amount 0   0    
Change in the fair value of the Evofem warrants 63,211 $ 63,211  
Percentage of additional shares     50.00%    
Derivative stated value $ 1,000   $ 1,000    
Additional premium percentage 50.00%   50.00%    
Patent licensing fees     $ 108,519 61,666  
Research and development expenses     1,973,532 9,698,626  
Sales and marketing costs $ 399,951 64,731 399,951 64,731  
Net loss attributable to non-controlling interest $ (138,850) $ (74,260) $ (381,006) $ (213,227)  
Series A-1 Convertible Preferred Stock [Member]          
Summary of Significant Accounting Policies [Line Items]          
Derivative shares (in Shares) 21,353   21,353    
Conversion amount     $ 500    
Derivative floor price amount $ 8,880   $ 8,880    
Series B-1 Convertible Preferred Stock [Member]          
Summary of Significant Accounting Policies [Line Items]          
Derivative shares (in Shares) 2,689   2,689    
Derivative floor price amount $ 8,120   $ 8,120    
Series B-2 Convertible Preferred Stock [Member]          
Summary of Significant Accounting Policies [Line Items]          
Derivative shares (in Shares) 2,625   2,625    
Derivative floor price amount $ 9,420   $ 9,420    
Pearsanta, Inc. [Member]          
Summary of Significant Accounting Policies [Line Items]          
Owns percentage 90.00%   90.00%    
Billed Revenues [Member]          
Summary of Significant Accounting Policies [Line Items]          
Accounts receivable $ 117,328   $ 117,328   120,296
Unbilled Revenues [Member]          
Summary of Significant Accounting Policies [Line Items]          
Accounts receivable $ 323   $ 323   $ 1,286